Six Protected Drug Classes Codified In Medicare Part D Under Draft Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Technical corrections bill could be passed in lame duck session after November elections.
You may also be interested in...
Part D Expected To Keep Protected Class Status Quo, Despite Bill Language
Although legal language does not mirror current CMS guidance, industry observers are expecting little change when it comes to the concept of covering "all or substantially all" drugs in the six protected classes under Medicare Part D once provisions of the new Medicare law are enacted
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.